148 related articles for article (PubMed ID: 19085437)
1. Cannabis using schizophrenia patients treated with atypical neuroleptics: do their symptoms differ from those of cannabis abstainers?
Schaub M; Fanghaenel K; Senn C; Stohler R
Subst Use Misuse; 2008 Dec; 43(14):2045-52. PubMed ID: 19085437
[TBL] [Abstract][Full Text] [Related]
2. Psychopharmacotherapy and remission of patients with schizophrenia.
Degmecić D; Pozgain I; Filaković P; Dodig-Curković K; Mihanović M
Coll Antropol; 2009 Jun; 33(2):547-51. PubMed ID: 19662777
[TBL] [Abstract][Full Text] [Related]
3. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls.
Schaub M; Fanghaenel K; Stohler R
Aust N Z J Psychiatry; 2008 Dec; 42(12):1060-5. PubMed ID: 19016094
[TBL] [Abstract][Full Text] [Related]
4. A comparison of drug use and dependence between blunt smokers and other cannabis users.
Timberlake DS
Subst Use Misuse; 2009; 44(3):401-15. PubMed ID: 19212929
[TBL] [Abstract][Full Text] [Related]
5. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
[TBL] [Abstract][Full Text] [Related]
6. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.
Karow A; Schnedler D; Naber D
Pharmacopsychiatry; 2006 Mar; 39(2):47-51. PubMed ID: 16555164
[TBL] [Abstract][Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
8. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.
Jockers-Scherübl MC; Rentzsch J; Danker-Hopfe H; Radzei N; Schürer F; Bahri S; Hellweg R
Neurosci Lett; 2006 Jun; 400(3):262-6. PubMed ID: 16540246
[TBL] [Abstract][Full Text] [Related]
9. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid relationships in former cannabis users with schizophrenia.
Monterrubio S; Solowij N; Meyer BJ; Turner N
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):280-5. PubMed ID: 16236415
[TBL] [Abstract][Full Text] [Related]
11. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
12. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis.
van Rossum I; Boomsma M; Tenback D; Reed C; van Os J;
J Nerv Ment Dis; 2009 Jan; 197(1):35-40. PubMed ID: 19155808
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Piskulić D; Olver JS; Maruff P; Norman TR
Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
[TBL] [Abstract][Full Text] [Related]
14. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
[TBL] [Abstract][Full Text] [Related]
15. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial.
Clausen L; Hjorthøj CR; Thorup A; Jeppesen P; Petersen L; Bertelsen M; Nordentoft M
Psychol Med; 2014 Jan; 44(1):117-26. PubMed ID: 23590927
[TBL] [Abstract][Full Text] [Related]
16. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
17. [Drug abuse experience and neuroleptic prescriptions at the onset of schizophrenia].
Lisoprawski A
Sem Hop; 1983 Jun; 59(25):1925-7. PubMed ID: 6136096
[TBL] [Abstract][Full Text] [Related]
18. [Validation of the Temporal Experience of Pleasure Scale (TEPS) in a French-speaking environment].
Favrod J; Ernst F; Giuliani F; Bonsack C
Encephale; 2009 Jun; 35(3):241-8. PubMed ID: 19540410
[TBL] [Abstract][Full Text] [Related]
19. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia.
Hamera E; Schneider JK; Deviney S
J Nerv Ment Dis; 1995 Sep; 183(9):559-65. PubMed ID: 7561817
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
